|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - Audentes Therapeutics Inc. (BOLD)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2019-06-24 Sale |
2019-06-26 4:07 pm |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
21,000 | $37.79 | $793,614 | 290,001 (Indirect Direct) |
View |
| 2019-05-13 Sale |
2019-05-15 4:42 pm |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $36.98 | $369,798 | 30,870 (Direct) |
View |
| 2019-03-25 Sale |
2019-03-27 5:03 pm |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
21,558 | $36 | $776,073 | 306,099 (Indirect Direct) |
View |
| 2019-02-25 Sale |
2019-02-27 4:32 pm |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $30.06 | $300,553 | 40,870 (Direct) |
View |
| 2019-02-25 Sale |
2019-02-27 4:31 pm |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
21,000 | $30 | $630,000 | 171,814 (Indirect Direct) |
View |
| 2018-12-24 Sale |
2018-12-27 5:43 pm |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
32,000 | $18.62 | $595,799 | 325,799 (Indirect Direct) |
View |
| 2018-11-15 Sale |
2018-11-16 6:34 pm |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
24,000 | $22.49 | $539,760 | 345,799 (Indirect Direct) |
View |
| 2018-10-01 Sale |
2018-10-02 7:05 pm |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $36.88 | $368,788 | 50,870 (Direct) |
View |
| 2018-10-01 Sale |
2018-10-02 7:04 pm |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
21,000 | $38.16 | $801,372 | 171,814 (Indirect Direct) |
View |
| 2018-09-28 Sale |
2018-10-02 7:03 pm |
Audentes Therapeutics Inc. | BOLD | GRAY JOHN T. SVP, Chief Scientific Officer |
87 | $40 | $3,480 | 71,669 (Direct) |
View |
| 2018-09-24 Sale |
2018-09-26 7:00 pm |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
33,000 | $37.38 | $1,233,380 | 365,999 (Direct Indirect) |
View |
| 2018-09-18 Sale |
2018-09-20 7:01 pm |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
12,952 | $40 | $518,080 | 171,814 (Indirect Direct) |
View |
| 2018-07-02 Sale |
2018-07-05 6:35 pm |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
4,989 | $38.02 | $189,704 | 65,881 (Direct) |
View |
| 2018-07-02 Sale |
2018-07-05 6:34 pm |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
71,048 | $39.55 | $2,809,837 | 171,814 (Indirect Direct) |
View |
| 2018-06-25 Sale |
2018-06-27 6:52 pm |
Audentes Therapeutics Inc. | BOLD | NEWMAN MARY VP |
8,545 | $40.79 | $348,581 | 15,272 (Direct) |
View |
| 2018-06-25 Sale |
2018-06-27 6:51 pm |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
33,000 | $40.59 | $1,339,498 | 386,939 (Direct Indirect) |
View |
| 2018-06-20 Sale |
2018-06-22 7:11 pm |
Audentes Therapeutics Inc. | BOLD | Nagler David VP |
5,000 | $45.29 | $226,461 | 32,347 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-06-05 Tax Withholding |
2019-06-07 4:42 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
757 | $37.31 | 17,479 (Direct) |
View |
| 2019-06-05 Tax Withholding |
2019-06-07 4:41 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
3,332 | $37.31 | 171,814 (Direct) |
View |
| 2019-06-05 Tax Withholding |
2019-06-07 4:41 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Holles Natalie C. COO |
1,009 | $37.31 | 55,714 (Direct) |
View |
| 2019-06-05 Tax Withholding |
2019-06-07 4:40 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Soloway Thomas P CFO |
1,009 | $37.31 | 22,324 (Direct) |
View |
| 2019-05-13 Exercise |
2019-05-15 4:42 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $0.79 | 30,870 (Direct) |
View |
| 2019-05-13 Exercise |
2019-05-15 4:42 pm |
N/A 2024-02-18 |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $0.79 | 30,870 (Direct) |
View |
| 2019-03-28 Option Award |
2019-04-01 5:54 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Meltz Mark A VP |
37,333 | $0 | 104,000 (Direct) |
View |
| 2019-03-28 Option Award |
2019-04-01 5:54 pm |
N/A 2029-03-28 |
Audentes Therapeutics Inc. | BOLD | Meltz Mark A VP |
104,000 | $37.26 | 104,000 (Direct) |
View |
| 2019-02-25 Exercise |
2019-02-27 4:32 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $0.79 | 40,870 (Direct) |
View |
| 2019-02-25 Exercise |
2019-02-27 4:32 pm |
N/A 2024-02-18 |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $0.79 | 40,870 (Direct) |
View |
| 2019-02-25 Exercise |
2019-02-27 4:31 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
17,000 | $0.78 | 171,814 (Direct) |
View |
| 2019-02-25 Exercise |
2019-02-27 4:31 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
4,000 | $2.19 | 171,814 (Direct) |
View |
| 2019-02-25 Exercise |
2019-02-27 4:31 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
17,000 | $0.78 | 171,814 (Direct) |
View |
| 2019-02-25 Exercise |
2019-02-27 4:31 pm |
N/A 2025-02-04 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
4,000 | $2.19 | 171,814 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:50 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
63,700 | $0 | 177,450 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:50 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
177,450 | $24.74 | 177,450 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:29 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Soloway Thomas P CFO |
23,333 | $0 | 65,000 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:29 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Soloway Thomas P CFO |
65,000 | $24.74 | 65,000 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:28 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Smith Julie Director |
16,200 | $24.74 | 16,200 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:27 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Schuetz Thomas J. Director |
16,200 | $24.74 | 16,200 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:25 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
17,500 | $0 | 48,750 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:25 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
48,750 | $24.74 | 48,750 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:23 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Morrison Scott W Director |
16,200 | $24.74 | 16,200 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:22 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | LANGE LOUIS G Director |
16,200 | $24.74 | 16,200 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:21 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Jarrett Jennifer Director |
16,200 | $24.74 | 16,200 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:20 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Holles Natalie C. COO |
23,333 | $0 | 65,000 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:20 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Holles Natalie C. COO |
65,000 | $24.74 | 65,000 (Direct) |
View |
| 2019-02-06 Option Award |
2019-02-08 5:20 pm |
N/A 2029-02-06 |
Audentes Therapeutics Inc. | BOLD | Goldberg Mark Alan Director |
16,200 | $24.74 | 16,200 (Direct) |
View |
| 2019-01-24 Exercise |
2019-01-25 7:28 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Holles Natalie C. COO |
8,300 | $2.765 | 156,429 (Direct) |
View |
| 2019-01-24 Exercise |
2019-01-25 7:28 pm |
N/A 2025-11-06 |
Audentes Therapeutics Inc. | BOLD | Holles Natalie C. COO |
8,300 | $2.765 | 156,429 (Direct) |
View |
| 2019-01-03 Option Award |
2019-01-04 4:48 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Mosbrooker Eric SVP, Chief Commercial Officer |
31,500 | $0 | 87,750 (Direct) |
View |
| 2019-01-03 Option Award |
2019-01-04 4:48 pm |
N/A 2029-01-03 |
Audentes Therapeutics Inc. | BOLD | Mosbrooker Eric SVP, Chief Commercial Officer |
87,750 | $22.01 | 87,750 (Direct) |
View |
| 2018-12-06 Exercise |
2018-12-10 4:39 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
40,000 | $0.78 | 171,814 (Direct) |
View |
| 2018-12-06 Exercise |
2018-12-10 4:39 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
40,000 | $0.78 | 171,814 (Direct) |
View |
| 2018-11-15 Option Award |
2018-11-16 6:41 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | NEWMAN MARY VP |
660 | $19.64 | 660 (Direct) |
View |
| 2018-11-15 Option Award |
2018-11-16 6:37 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
736 | $19.64 | 736 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:05 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
100 | $0.79 | 50,870 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:05 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
1,101 | $0.79 | 50,870 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:05 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
3,900 | $0.79 | 50,870 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:05 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
200 | $0.79 | 50,870 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:05 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
4,699 | $0.79 | 50,870 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:05 pm |
N/A 2024-02-18 |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
10,000 | $0.79 | 50,870 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:04 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
2,144 | $0.78 | 171,814 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:04 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
5,330 | $0.78 | 171,814 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:04 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
5,448 | $0.78 | 171,814 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:04 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
8,078 | $0.78 | 171,814 (Direct) |
View |
| 2018-10-01 Exercise |
2018-10-02 7:04 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
21,000 | $0.78 | 171,814 (Direct) |
View |
| 2018-09-28 Exercise |
2018-10-02 7:03 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | GRAY JOHN T. SVP, Chief Scientific Officer |
87 | $1.05 | 71,669 (Direct) |
View |
| 2018-09-28 Exercise |
2018-10-02 7:03 pm |
N/A 2024-09-17 |
Audentes Therapeutics Inc. | BOLD | GRAY JOHN T. SVP, Chief Scientific Officer |
87 | $1.05 | 71,669 (Direct) |
View |
| 2018-09-24 Exercise |
2018-09-24 6:12 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
15,000 | $0.78 | 171,814 (Direct) |
View |
| 2018-09-24 Exercise |
2018-09-24 6:12 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
15,000 | $0.78 | 171,814 (Direct) |
View |
| 2018-09-18 Exercise |
2018-09-20 7:01 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
12,952 | $2.19 | 171,814 (Direct) |
View |
| 2018-09-18 Exercise |
2018-09-20 7:01 pm |
N/A 2025-02-04 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
12,952 | $2.19 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:35 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
4,989 | $0.79 | 65,881 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:35 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
5,011 | $0.79 | 65,881 (Direct) |
View |
| 2018-07-02 Sale |
2018-07-05 6:35 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
5,011 | $38.79 | 65,881 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:35 pm |
N/A 2024-02-18 |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
4,989 | $0.79 | 65,881 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:35 pm |
N/A 2024-02-18 |
Audentes Therapeutics Inc. | BOLD | PRASAD SUYASH Senior VP & Chief Med Officer |
5,011 | $0.79 | 65,881 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
19,599 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
1,401 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
26,901 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
23,147 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
19,599 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
1,401 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
26,901 | $0.78 | 171,814 (Direct) |
View |
| 2018-07-02 Exercise |
2018-07-05 6:34 pm |
N/A 2023-09-25 |
Audentes Therapeutics Inc. | BOLD | Patterson Matthew R CEO |
23,147 | $0.78 | 171,814 (Direct) |
View |
| 2018-06-25 Exercise |
2018-06-27 6:52 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | NEWMAN MARY VP |
8,245 | $2.185 | 15,272 (Direct) |
View |
| 2018-06-25 Exercise |
2018-06-27 6:52 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | NEWMAN MARY VP |
300 | $2.185 | 15,272 (Direct) |
View |
| 2018-06-25 Exercise |
2018-06-27 6:52 pm |
N/A 2025-02-04 |
Audentes Therapeutics Inc. | BOLD | NEWMAN MARY VP |
8,545 | $2.185 | 15,272 (Direct) |
View |
| 2018-06-20 Exercise |
2018-06-22 7:11 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Nagler David VP |
4,700 | $2.185 | 32,347 (Direct) |
View |
| 2018-06-20 Exercise |
2018-06-22 7:11 pm |
N/A N/A |
Audentes Therapeutics Inc. | BOLD | Nagler David VP |
300 | $2.185 | 32,347 (Direct) |
View |
| 2018-06-20 Exercise |
2018-06-22 7:11 pm |
N/A 2025-02-04 |
Audentes Therapeutics Inc. | BOLD | Nagler David VP |
5,000 | $2.185 | 32,347 (Direct) |
View |
| 2018-06-08 Option Award |
2018-06-08 5:24 pm |
N/A 2028-06-08 |
Audentes Therapeutics Inc. | BOLD | Smith Julie Director |
10,000 | $38.65 | 10,000 (Direct) |
View |
| 2018-06-08 Option Award |
2018-06-08 5:23 pm |
N/A 2028-06-08 |
Audentes Therapeutics Inc. | BOLD | Schuetz Thomas J. Director |
10,000 | $38.65 | 10,000 (Direct) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Wed, 26 Jun 2019 19:16:32 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |